glp 1 agonist oral GLP-1: A Needle-Free Solution for Weight Loss GLP-1 Agonists For Obesity In

Utilization of PBPK Modeling Approaches to Assess DDIs Caused by Mechanisms of Actions Evaluating the mechanism of action (eg, delayed gastric emptying, reduced fat mass and inflammation, and changes in GFR)-mediated DDIs of GLP-1 RAs and a dual GLP-1/GIP RA is often challenging to control for and clinical studies are costly

Amycretin is a next-generation unimolecular dual GLP-1/amylin receptor agonist that showed up to 24.3% weight loss in early trials, substantially exceeding semaglutide and potentially exceeding even CagriSema

However, further research is needed to determine who may be at greatest risk and whether certain dosing strategies could mitigate these complications

Some plans may cover these treatments when prescribed for a qualifying diagnosis such as obesity (BMI 30) or overweight (BMI 27) with a weight-related comorbidity

Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia

Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: A narrative review and practical considerations for primary care providers